PEP Sample Clauses

PEP. If Customer has not previously opted out of participating in Sage’s Product Enhancement Program (“PEP”) Customer may automatically be enrolled in PEP when it installs the Program. Customer may disable PEP during its use of the Software. Through PEP, Sage may collect information on Customer’s hardware and when Customer installs the Software, and how Customer uses the Software and its in-product help and services. This information helps Sage identify trends and usage patterns to improve the quality of the products and services Sage offers. Additionally, Sage may collect information through PEP to enforce its rights under this Agreement (e.g., number of users for licensing, serial numbers, and registration numbers), and if a user updates user information via a request prompted by the Software, information provided will be stored in PEP and used to update Sage’s customer records.
PEP. To the knowledge of each Loan Party, no Loan Party nor any of their respective Subsidiaries is acting on behalf of any corporation, business or other entity that has been formed by, or for the benefit of, a current or former senior foreign political figure, serving in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government owned corporation, or political figure (collectively, a “PEP”).
PEP. General‌ Certificated classroom teachers and certificated support personnel holding non-administrative positions (collectively referred to as “employees” herein) shall be evaluated during each school year in accordance with the procedures and criteria set forth herein.
PEP. 4.9.1 As detailed in Section 2, PEP packs are currently supplied to a number of settings in a 30-day pack with the manufacturers’ original packs of licensed medicine, over labelled with instructions for use, ready for issue by healthcare professionals. The medicine used is: Tenofovir disoproxil 245 mg + Emtricitabine 200 mg; and Raltegravir 600mg 4.9.2 Bidders wishing to provide an over labelled PEP pack service, must submit a Price for the provision of the service within Document No. 05b, Sheet 3, PEP Packaging. 4.9.3 Offerors Prices must be inclusive of all additional requirements to produce a pack, which includes the label, storage, and distribution to the nominated sites. Appendix A and Schedule 8, Document No. 03 lists the participating authorities to the framework agreement, that will be responsible for placing and payment of all orders for delivery of over-labelled packs. The minimum quantity being 30 packs 4.9.4 Volumes for over labelled PEP packs have been included within Document No. 05b, Sheet 3, PEP packaging.
PEP. To the knowledge of the Borrower, none of the Loan Parties nor any of their respective Subsidiaries is acting on behalf of any corporation, business, or other entity that has been formed by, or for the benefit of, a current or former senior foreign political figure, serving in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation, or political figure (collectively, a “PEP”). Moreover, to the knowledge of the Borrower, none of the Loan Parties nor any of their respective Subsidiaries maintains a close relationship with a PEP or a parent, sibling, spouse or child or in-law of a PEP.
PEP. 2.7.1 Post-Exposure Prophylaxis (PEP) involves two HIV medicines given to people who are HIV negative to reduce their risk of acquiring HIV if they are exposed to the virus. 2.7.2 PEP is a short course treatment following sexual exposures, occupational exposures and other non-occupational exposures in the community and is taken soon after a possible exposure to HIV to prevent the virus from taking hold. 2.7.3 PEP is used only in emergency situations. It is not meant for regular use by people who may be exposed to HIV frequently. It is envisaged that over time the requirement for PEP will reduce as more people access PrEP for prevention. 2.7.4 PEP is currently delivered to a number of settings, that include hospital accident and emergency departments and sexual assault and referral clinics in an over labelled pack ready for dispensing by practitioners. 2.7.5 In 2022, the Authority streamlined the number of different size packs to a standard 30-day pack. This was so that the licensed medicines could be packed in their original packaging and to align with the recommended BHIVA guidance of a minimum 28 - day course for people that may have been at risk of HIV transmission.
PEP 

Related to PEP

  • Treatment of Company Equity Awards (a) At the Effective Time, each outstanding Company RSU shall, automatically and without any required action on the part of the holder thereof, cease to represent a restricted stock unit denominated in shares of Company Common Stock and shall be converted into a restricted stock unit denominated in shares of Parent Common Stock (each, a “Parent RSU”). The number of shares of Parent Common Stock subject to each such Parent RSU shall be equal to the product (rounded to the nearest whole number) of (x) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time multiplied by (y) the Equity Exchange Ratio. Except as specifically provided above, following the Effective Time, each such Parent RSU shall continue to be governed by the same terms and conditions (including vesting and forfeiture terms) as were applicable to the corresponding Company RSU immediately prior to the Effective Time, but shall be treated as if a “change in control” has occurred in accordance with Section 6.13(d). Dividend equivalent rights associated with Company RSUs that are denominated in Company RSUs shall be treated consistent with this Section 3.2(b) and such rights denominated in cash shall be provided for in the Parent RSU and shall continue to be governed by the same terms and conditions (including vesting and forfeiture terms) as were applicable to the corresponding Company RSU immediately prior to the Effective Time. (b) At the Effective Time, each outstanding Company PSU shall, automatically and without any required action on the part of the holder thereof, cease to represent a performance stock unit denominated in shares of Company Common Stock and shall be converted into a Parent RSU. The number of shares of Parent Common Stock subject to each such Parent RSU shall be equal to the product (rounded to the nearest whole number) of (x) the sum of (i) the number of shares of Company Common Stock subject to such Company PSU immediately prior to the Effective Time that are subject to the performance period in which the Effective Time occurs, based on the greater of target performance and actual performance as determined by the Company Board (or, if appropriate, any committee thereof administering the Company Equity Plans) in accordance with the terms of the Company Equity Plans and applicable award agreements, plus (ii) the number of shares of Company Common Stock subject to such Company PSU immediately prior to the Effective Time that are subject to any performance period that begins after the Effective Time, based on target performance, multiplied by (y) the Equity Exchange Ratio. Except as specifically provided above, following the Effective Time, each such Parent RSU shall continue to be governed by the same terms and conditions (including vesting and forfeiture terms) as were applicable to the corresponding Company PSU immediately prior to the Effective Time, but (X) shall no longer be subject to any performance-based vesting conditions and (Y) shall be treated as if a “change in control” has occurred in accordance with Section 6.13(d). Dividend equivalent rights associated with Company PSUs that are denominated in Company PSUs shall be treated consistent with this Section 3.2(b) and such rights denominated in cash shall be provided for in the Parent RSU and shall continue to be governed by the same terms and conditions (including vesting and forfeiture terms) as were applicable to the corresponding Company PSU immediately prior to the Effective Time. (c) At the Effective Time, each outstanding Company Restricted Stock Award shall, automatically and without any required action on the part of the holder thereof, cease to represent a restricted share of Company Common Stock and shall be converted into a number of restricted shares of Parent Common Stock (each, a “Parent Restricted Stock Award”) equal to the product (rounded to the nearest whole number) of the Equity Exchange Ratio multiplied by the number of shares of Company Common Stock subject to such Company Restricted Stock Award immediately prior to the Effective Time. Except as specifically provided above, following the Effective Time, each such Parent Restricted Stock Award shall continue to be governed by the same terms and conditions (including vesting and forfeiture terms) as were applicable to the corresponding Company Restricted Stock Award immediately prior to the Effective Time, but (X) shall no longer be subject to any performance-based vesting conditions and